Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Atea Pharmaceuticals (AVIR) Strong Sell-Off 'Premature' - William Blair
October 19, 2021 10:55 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Atea Pharmaceuticals (NASDAQ: AVIR) amid today's sell-off, calling it "premature."
The analyst commented, "While the top-line miss in the Phase II MOONSONG study is a setback for Atea, we... More
Atea Pharmaceuticals Inc. (AVIR) to Resume Trading at 7:30 a.m.
October 19, 2021 7:10 AM EDTAtea Pharmaceuticals Inc. (NASDAQ: AVIR) to Resume Trading at 7:30 a.m.
... MoreMerck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint
October 19, 2021 7:09 AM EDTMerck (NYSE: MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trial Missing Primary Endpoint
Merck up 2.2%, Atea Still Halted... More